The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape
Goebell P, Doehn C, Gruellich C, Gruenwald V, Steiner T, Ehness R, Welslau M (2017)
Publication Type: Journal article
Publication year: 2017
Journal
Book Volume: 13
Pages Range: 1463-1471
Journal Issue: 17
Abstract
VEGFR and mTOR inhibitors are broadly used in metastatic renal cell carcinoma (mRCC) therapy, and sequential first-line pazopanib (VEGFR inhibitor) and second-line everolimus (mTOR inhibitor) is a standard treatment option. Nivolumab and lenvatinib/everolimus combination was recently approved in Europe for use in mRCC after previous therapy. Prospective routine data on sequential therapy including nivolumab and/or lenvatinib are missing. This is a prospective, noninterventional study, which evaluates the effectiveness, tolerability, safety and quality of life following 450 patients with mRCC starting either on pazopanib as first-line therapy or third-line everolimus plus/minus lenvatinib following nivolumab. Adults with histologically confirmed mRCC of any subtype, who have a life expectancy of at least 6 months, are eligible.
Authors with CRIS profile
Involved external institutions
Novartis AG
Switzerland (CH)
HELIOS Kliniken
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Klinikum Aschaffenburg
Germany (DE)
Switzerland (CH)
HELIOS Kliniken
Germany (DE)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Klinikum Aschaffenburg
Germany (DE)
How to cite
APA:
Goebell, P., Doehn, C., Gruellich, C., Gruenwald, V., Steiner, T., Ehness, R., & Welslau, M. (2017). The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. Future Oncology, 13(17), 1463-1471. https://doi.org/10.2217/fon-2017-0083
MLA:
Goebell, Peter, et al. "The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape." Future Oncology 13.17 (2017): 1463-1471.
BibTeX: Download